Recent research has highlighted the importance of glucagon-like peptide-1 (GLP-1) and its analogs in this context, as they play a significant role in beta-cell function and survival. Various ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Two major forms of diabetes exist, type 1 and type 2. Type 1 diabetes is characterized by a complete lack of insulin that leads to an inability of cells ... such as glucagon-like peptide-1 ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists ... strengthen connections ...

Long-acting pharmacotherapies targeting incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent ... uncoupler dinitrophenol or beta-adrenergic activation, these approaches ...